Filter
4040
Text search:
vaccination
Featured
440
959
Language
3142
800
202
125
125
78
60
46
34
25
15
15
14
13
11
11
10
9
8
8
7
6
6
6
5
5
5
5
5
4
4
4
4
3
3
3
3
3
3
3
3
3
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Document type
1682
703
629
251
243
201
92
68
62
46
35
15
11
Countries
175
153
131
87
79
79
68
64
64
63
63
61
58
56
55
53
52
52
52
51
49
46
45
44
40
36
34
34
33
32
32
31
30
28
27
27
27
27
26
25
24
22
22
22
22
21
20
19
18
18
16
16
16
15
14
14
13
13
12
11
11
11
10
10
9
8
8
8
7
7
6
6
6
6
6
5
5
5
5
5
4
4
4
4
3
3
3
3
3
3
3
3
3
3
3
3
2
2
2
2
2
2
2
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Authors & Publishers
706
145
117
85
84
76
54
51
49
42
38
37
36
34
33
30
29
27
26
26
24
22
18
17
16
16
16
15
15
14
14
13
12
12
12
12
11
11
11
11
11
11
11
11
11
11
10
10
10
10
10
10
10
9
9
9
9
9
9
9
8
8
8
8
8
8
8
8
8
8
8
8
8
7
7
7
7
7
7
7
7
7
7
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Publication Years
1784
1974
262
20
Category
1665
342
222
197
171
44
27
2
Toolboxes
789
182
158
149
130
122
109
102
88
87
85
83
80
77
72
71
54
48
43
42
35
30
21
6
5
1
The UNHCR Cholera Response Plan (October 2022 – March 2023) outlines efforts to combat the cholera outbreak in Lebanon, which was declared in October 2022. The plan, led by the Ministry of Public Health with support from UNHCR, WHO, UNICEF, and NGOs, focuses on prevention, response, and surveillan
...
ce. Key actions include oral cholera vaccination campaigns, rapid diagnostics, strengthening healthcare facilities, and improving hygiene and sanitation in high-risk refugee settlements and collective shelters. The response also emphasizes risk communication and community engagement to raise awareness and ensure early detection. The plan targets 120,000 individuals and requires $8.5 million in funding to provide life-saving support and containment measures.
more
Development assistance for health (DAH), the value of which peaked in 2013 and fell in 2015, is unlikely to rise substantially in the near future, increasing reliance on domestic and innovative financing sources to sustain health programmes in low-income and middle-income countries. We examined inno
...
vative financing instruments (IFIs)—financing schemes that generate and mobilise funds—to estimate the quantum of financing mobilised from 2002 to 2015. We identified ten IFIs, which mobilised US$8·9 billion (2·3% of overall DAH) in 2002–15. The funds generated by IFIs were channelled mostly through GAVI and the Global Fund, and used for programmes for new and underused vaccines, HIV/AIDS, malaria, tuberculosis, and maternal and child health. Vaccination programmes received the largest amount of funding ($2·6 billion), followed by HIV/AIDS ($1080·7 million) and malaria ($1028·9 million), with no discernible funding targeted to non-communicable diseases.
more
WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines.
Updated risk rates for hospital admission in patients with non-severe COVID-19
The guidance includes updated risk rates for
...
hospital admission in patients with non-severe COVID-19.
The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients.
This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines:
**High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%.
**Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%.
Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk.
Review of COVID-19 treatments for people with non-severe COVID-19
WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022.
If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead.
WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission.
For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol.
WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials.
The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials.
more
Response to the Periodic EpidemicThe document "Zanzibar's Victory Against Cholera Epidemic" details the successful efforts taken by Zanzibar to control and eliminate cholera outbreaks. It highlights the strategies implemented, including improved water and sanitation infrastructure, public health cam
...
paigns, vaccination programs, and rapid response measures. The report emphasizes community engagement, government commitment, and international partnerships as key factors in combating the disease. Zanzibar's experience serves as a model for other regions facing similar public health challenges, demonstrating that sustained efforts in hygiene, disease surveillance, and emergency preparedness can effectively control cholera epidemics.
more
The document is a comprehensive practical guide for managing cholera epidemics. It includes detailed instructions on outbreak investigation, control measures, case management, and the organization of treatment facilities. It emphasizes strategies such as rehydration therapy, water sanitation, hygien
...
e promotion, and vaccination to prevent the spread of cholera. The guide serves as a resource for healthcare professionals, logisticians, and public health officials to respond effectively to cholera outbreaks.
more
WHO has published the first-ever guidance on the clinical management of diphtheria. The only previously available guidance was an operational protocol. The new guidance followed the rigorous process for developing guidance at WHO.
It addresses the use of Diphtheria Antitoxin (DAT) in the treatmen
...
t of diphtheria. There is a worldwide shortage of DAT and evidence based recommendations on the use of DAT were requested by many Member States.
The guidance also includes new recommendations on antibiotics. In patients with suspected or confirmed diphtheria, WHO recommends using macrolide antibiotics (azithromycin, erythromycin) rather than penicillin antibiotics.
This clinical practice guideline has been rapidly developed recognizing the global increase in diphtheria outbreaks. Outbreaks of diphtheria in Nigeria, Guinea and neighbouring countries in 2023 have highlighted the urgent need for evidence-based clinical practice guidelines for the treatment of diphtheria. Given the sporadic nature of outbreaks, many clinicians in the affected regions have never managed acute diphtheria and its related complications. Diphtheria remains a neglected disease and vaccination is the top priority. At the same time, for patients with diphtheria, access to antibiotics, DAT and supportive care can be lifesaving.
more
As the Americas undergo profound demographic change and there are more persons aged 65 years or older than children younger than 5 years, it is crucial to recognize that national immunization programs must be redesigned to ensure comprehensive protection for individuals across the lifespan. By adopt
...
ing a life course approach (LCA) to immunization, vaccination programs can be tailored to close immunity gaps at different stages of life. The life course approach foresees the establishment of multiple strategies to reduce missed opportunities for vaccination according to age group. This technical document explains the key concepts of the LCA with a focus on immunization by vaccination, as well as the underlying biological mechanisms that require the application different vaccines at different life stages according to changes to the immune system and in the epidemiological situation of a community.
more
En 2023, la nouvelle stratégie de Coopération de l’OMS avec le Niger 2023-2027 a été lancée, assortie d’un plan d’investissement. En outre, l’OMS a soutenu plusieurs initiatives majeures du pays, comme le lancement effectif de la Stratégie nationale de la Couverture Sanitaire Universel
...
le (CSU) 2023-2030, la mise à jour de la Stratégie nationale de financement de la santé, la mise en œuvre de la stratégie Triage, Évaluation et Traitement des Urgences pédiatriques (TETU) dans plusieurs régions. De nombreuses actions ont aussi été menées dans d’autres domaines, comme la riposte apportée à l’épidémie de diphtérie, le soutien continu à la vaccination de routine, l’appui au maintien de la chaine du froid pour les vaccins (menacée par l’interruption de la fourniture d’énergie), etc.
more
Neonatal tetanus (NT), a severe newborn illness from the toxigenic strains of Clostridium tetani, persists in middle- and low-income countries due to non-sterile childbirth practices. Unlike smallpox and polio, tetanus cannot be eradicated: Clostridium tetani spores exist in the environment, and ani
...
mal reservoirs. However, elimination as a public health issue is achievable through widespread tetanus vaccination, clean deliveries, and proper umbilical cord care. The goal of eliminating maternal and neonatal tetanus (MNT) as a public health problem is considered met when all municipalities in a country have an annual incidence rate of NT of less than 1 case per 1000 live births. The Region of the Americas achieved the maternal and neonatal tetanus elimination (MNTE) target in 2017 when elimination was validated in the Republic of Haiti. Yet maintaining this progress requires continued efforts. High vaccination coverage, booster doses in countries lacking them, hygienic practices, and strong maternal and child health services are key. The Pan American Health Organization’s (PAHO) integrated maternal and neonatal immunization platform further strengthens this fight against early childhood diseases.
more
L’orthopoxvirus simien ou virus de la variole du singe (MPXV), est un virus à ADN double brin qui appartient au genre Orthopoxvirus de la famille
des Poxviridés. Les poxvirus causent des maladies chez l’espèce humaine et beaucoup d’autres animaux ; l’infection se manifeste généralement
...
par la formation de lésions, de nodules cutanés ou d’une éruption cutanée disséminée. Les autres espèces d’orthopoxvirus (OPXV) pathogènes pour l’être humain comprennent le virus de la variole bovine et le virus variolique (responsable de la variole, qui a été éradiquée). Le virus de la vaccine est également un OPXV qui a été utilisé pour la vaccination humaine, et a été un outil essentiel pour l’éradication de la variole, obtenue en 1980. Le MPXV doit son nom au fait qu’il a été identifié pour la première fois chez le singe. Le MPXV se retrouve principalement chez les rongeurs, mais son réservoir reste indéterminé. Il existe deux clades connus du MPXV, l’un endémique en Afrique de l’Ouest, et l’autre dans la région du bassin du Congo.
more
Conformément à son mandat, qui prévoit
qu’elle fournisse aux États Membres des orientations à caractère normatif en matière de
politique sanitaire, l’OMS publie une série de
notes de synthèse régulièrement mises à jour
sur les vaccins et les associations vaccinales
contre les ma
...
ladies ayant une incidence sur la
santé publique internationale. Ces notes de
synthèse portent essentiellement sur l’utilisation des vaccins dans le cadre de programmes
de vaccination à grande échelle.
more
La vidéo "Choléra - Questions & Réponses" de l'Organisation Mondiale de la Santé (OMS) explique les aspects essentiels du choléra, une maladie diarrhéique aiguë causée par l'ingestion d'eau ou d'aliments contaminés par la bactérie Vibrio cholerae. Elle met en avant les principaux symptôme
...
s, notamment une diarrhée aqueuse sévère, des vomissements et une déshydratation rapide, pouvant être mortelle sans traitement adéquat. La transmission se fait principalement par l’eau insalubre et les mauvaises conditions sanitaires. Pour prévenir la maladie, il est essentiel d'avoir accès à de l'eau potable, d'améliorer l'hygiène et l'assainissement, et d'utiliser la vaccination dans les zones à haut risque. En cas d'infection, la réhydratation orale ou intraveineuse est le traitement principal, tandis que les antibiotiques sont parfois administrés dans les cas graves. La vidéo insiste sur l'importance d'une intervention rapide et de mesures préventives pour limiter la propagation du choléra et protéger les populations à risque.
more
The video "Cholera - Questions & Answers" by the World Health Organization (WHO) explains the essential aspects of cholera, an acute diarrheal disease caused by ingesting water or food contaminated with the Vibrio cholerae bacterium. It highlights the main symptoms, including severe watery diarrhea,
...
vomiting, and rapid dehydration, which can be fatal without proper treatment. Transmission occurs primarily through unsafe water and poor sanitation conditions. To prevent the disease, it is crucial to have access to clean drinking water, improve hygiene and sanitation, and use vaccination in high-risk areas. In case of infection, oral or intravenous rehydration is the primary treatment, while antibiotics are sometimes administered in severe cases. The video emphasizes the importance of rapid intervention and preventive measures to limit the spread of cholera and protect at-risk populations.
more
The World Health Organization (WHO) African Region website provides comprehensive information on cholera outbreaks across the continent. In 2024, 14 countries, including the Democratic Republic of the Congo, Ethiopia, and Nigeria, experienced significant outbreaks, with these three nations categoriz
...
ed as being in acute crisis.
The site offers access to Monthly Regional Cholera Bulletins, such as the May 2024 edition, which details the status of outbreaks, affected countries, and response measures.
Additionally, the website emphasizes the importance of coordinated responses to cholera outbreaks, highlighting efforts to enhance surveillance, provide medical supplies, and implement vaccination campaigns in high-risk areas.
Overall, the WHO African Region's cholera page serves as a vital resource for understanding the scope of cholera outbreaks and the ongoing initiatives to control and prevent the disease across the continent.
more
The report provides an update on the cholera outbreak in Haiti as of January and February 2024. A total of 79,411 suspected cases have been reported, with 4,608 confirmed cases and 1,172 deaths across all 10 departments. The most affected regions include Ouest, Centre, Artibonite, and Nord, with chi
...
ldren aged 1-9 being the most impacted. Despite a recent decline in reported cases, underreporting due to security issues remains a concern. Response efforts include coordination meetings, epidemiological surveillance, case management, WASH interventions, vaccination campaigns, and community engagement. However, logistical challenges, insecurity, and funding shortages are hindering effective response efforts.
more
L'article souligne que les épidémies de choléra en Syrie et au Liban menacent gravement la santé et la survie des enfants. L'UNICEF alerte sur l'augmentation rapide des cas, exacerbée par des infrastructures d'eau et d'assainissement défaillantes, ainsi que par des systèmes de santé fragilis
...
és. L'organisation appelle à une action urgente pour améliorer l'accès à l'eau potable, renforcer les services de santé et mener des campagnes de vaccination afin de protéger les enfants contre cette maladie potentiellement mortelle.
more
L’année 2024 a été particulièrement éprouvante pour les enfants. Face à l’intensification des conflits violents, des chocs climatiques et de la pauvreté, leurs besoins n’ont en effet cessé de croître tandis que les ressources disponibles pour y répondre ont continué de diminuer.
...
Comme le montre notre Rapport annuel, l’UNICEF a néanmoins été présent dans plus de 190 pays et territoires, sauvant et améliorant la vie de millions d’enfants, y compris dans les endroits les plus difficiles d’accès. Avec l’aide de nos partenaires, nous avons œuvré à fournir de l’eau salubre et des installations d’assainissement, ainsi que des services de protection, de soutien psychosocial, de santé, de nutrition, de vaccination, d’éducation et de développement des compétences.
Alors que 2025 s’ouvre dans un contexte d'instabilité persistante, de bouleversements politiques, d'incertitude économique et de multiplication des crises humanitaires, l’organisation doit plus que jamais donner le meilleur d’elle-même. Or, les coupes annoncées et attendues dans les financements de l’aide internationale limitent notre capacité à venir en aide aux millions d’enfants les plus vulnérables.
more
National Malaria Elimination Strategic Plan (NMESP) 2024–2028
National Malaria Elimination Programme (NMEP)
Ghana Health Service - Ministry of Health, Ghana
(2023)
C2
The National Malaria Elimination Strategic Plan (NMESP) 2024–2028 of Ghana outlines the country’s roadmap to shift from malaria control to elimination. Despite major progress—like reducing malaria deaths from nearly 2,800 in 2012 to 151 in 2022—malaria remains a major public health challenge
...
in Ghana.
The plan aims to reduce malaria deaths by 90% and cases by 50% by 2028 (compared to 2022), and to eliminate malaria entirely in 21 low-burden districts. It includes a mix of interventions such as insecticide-treated nets, indoor residual spraying, seasonal chemoprevention, malaria vaccination, and strong surveillance systems.
The strategy is tailored to the local malaria burden, promotes community engagement, relies on multisectoral partnerships, and ensures adequate resource mobilization. Its ultimate goal is to protect Ghana’s population, improve public health, and support the country’s socioeconomic development.
more
The CDC Yellow Book is the Centers for Disease Control and Prevention's comprehensive reference guide to health issues related to international travel. It provides evidence-based recommendations and practical guidance for healthcare professionals advising travellers, as well as for travellers themse
...
lves. Topics covered include country-specific vaccination requirements, the prevention and treatment of infectious diseases, malaria prophylaxis, food and water safety, the management of travel-related conditions, and guidance for special populations, such as children, pregnant travellers and individuals with chronic illnesses. Updated every two years, the Yellow Book synthesises global surveillance data, World Health Organization guidelines and CDC expertise to help prevent illness and injury during international travel. Serving as both an authoritative clinical tool and a public health resource, it ensures safe and healthy travel worldwide.
Accessed on 27/08/2025.
more
Published by the World Health Organization, International Travel and Health 2012 provides comprehensive guidance on the health risks associated with international travel, as well as practical measures to prevent or reduce adverse health outcomes. Although the book is primarily intended for medical a
...
nd public health professionals who advise travellers, it is also useful for travel agents, transport providers and informed travellers. It covers a variety of topics, such as preventing infectious diseases, environmental hazards, accident risks, vaccination requirements, malaria prophylaxis and travel medical kits. Particular attention is given to travellers visiting friends and relatives, those travelling at short notice, and those journeying to remote or high-risk destinations. Recommendations are based on individual health status, destination, travel duration and behaviour. The publication emphasises the shared responsibility of travellers, healthcare providers and the travel industry in promoting safe travel and minimising preventable illnesses. Online updates provide real-time information on outbreaks, vaccine guidance and disease distribution.
more
